title: Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.
abstract: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS).
  
  
  
  A cross-sectional observational study.
  
  
  
  The data reported were from 17 MS units throughout Spain.
  
  
  
  Adult patients with relapsing-remitting MS.
  
  
  
  A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration.
  
  
  
  Patients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT.
  
  
  
  Patient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk-benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.
authors.affiliation: Department of Neurology, Hospital Universitario Quirónsalud, Madrid, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Arroyo
authors.affiliation: Department of Neurology, Hospital General Universitario de Alicante, Alicante, Spain.
authors.forename: Angel P
authors.initials: AP
authors.lastname: Sempere
authors.affiliation: Health Economics and Outcomes Research Unit, Roche Farma SA, Madrid, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Ruiz-Beato
authors.affiliation: Medical Department, Roche Farma SA, Madrid, Spain.
authors.forename: Daniel
authors.initials: D
authors.lastname: Prefasi
authors.affiliation: Health Economics and Outcomes Research, IMS Health, Barcelona, Spain.
authors.forename: Agata
authors.initials: A
authors.lastname: Carreño
authors.affiliation: Health Economics and Outcomes Research, IMS Health, Barcelona, Spain.
authors.forename: Montse
authors.initials: M
authors.lastname: Roset
authors.affiliation: Medical Department, Roche Farma SA, Madrid, Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Maurino
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D003657:Decision Making; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D057240:Patient Preference; D012008:Recurrence; D012044:Regression Analysis; D055502:Secondary Prevention / Q000379:methods; D013030:Spain; D011795:Surveys and Questionnaires
chemical_list: D007155:Immunologic Factors
keywords: conjoint analysis; disease-modifying therapies; patient preferences; rating-based experiment